Pre-exercise inhalation of short-acting ß-agonists (SABA) safely improves exercise performance in severe COPD patients by reducing lung hyperinflation

R. Tanaka, M. Miura, Y. Tashiro, S. Yamagata, M. Nihei, T. Hosaka (Sendai, Japan)

Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Session: Bronchodilator treatment for asthma and COPD
Session type: Thematic Poster Session
Number: 1192
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Tanaka, M. Miura, Y. Tashiro, S. Yamagata, M. Nihei, T. Hosaka (Sendai, Japan). Pre-exercise inhalation of short-acting ß-agonists (SABA) safely improves exercise performance in severe COPD patients by reducing lung hyperinflation. Eur Respir J 2010; 36: Suppl. 54, 1192

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effects of inhaled formoterol on dynamic hyperinflation during and after incremental treadmill exercise in patients with advanced COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 172s
Year: 2006

Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 33s
Year: 2006

Metronome-paced hyperventilation, CT measurements and exercise to investigate dynamic hyperinflation contrasting tiotropium versus indacaterol treatment in moderate COPD patients
Source: International Congress 2015 – Unravelling the mechanisms of symptoms and exercise limitationas in disease
Year: 2015


Effects of supplemental oxygen and high-dose inhaled bronchodilator therapy in exercise performance and dyspnoea in patients with stable COPD
Source: Annual Congress 2004 - Exercise and systemic effects in COPD
Year: 2004


Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006


The effect of tiotropium on lung dynamic hyperinflation and treadmill exercise capacity in mild to moderate COPD
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012

Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long-term inhaled corticosteroids (ICS) on FEV1-decline in patients with mild-to-moderate COPD
Source: Annual Congress 2010 - COPD: management
Year: 2010

Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Assessment of lung volumes and capacities in bronchodilator reversibility changes of hyperinflation of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016

LABA-LAMA combination is superior to LABA monotherapy in improving the cardiocirculatory responses to treadmill exercise in patients with moderate-to-severe COPD
Source: Annual Congress 2010 - Exercise in COPD
Year: 2010


The improvements of lung function tests after formoterol administration in COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 323s
Year: 2004

Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease
Source: Annual Congress 2006 - Recent advances in the treatment of COPD
Year: 2006


Effects of inhaled furosemide on exercise capacity and on dyspnea in patients with COPD
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

Lung hyperinflation, dyspnoe, and exercise tolerance in patients with COPD exacerbation
Source: Annual Congress 2010 - COPD exacerbation
Year: 2010


Evaluation of the response of airway obstruction to short-acting inhaled broncodilators with using FIV1 and FEV1 in COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 290s
Year: 2005

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
Source: Eur Respir J 2004; 23: 832-840
Year: 2004



Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017


Exercise and dyspnoea in COPD
Source: Eur Respir Rev 2006; 15: 72-79
Year: 2006